Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
ICD-10 N01.3 is a billable code used to indicate a diagnosis of rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis.
Rapidly progressive nephritic syndrome (RPNS) is characterized by a swift decline in renal function, often leading to end-stage renal disease within weeks to months. This condition is associated with diffuse mesangial proliferative glomerulonephritis, which is marked by an increase in mesangial cell proliferation and matrix deposition in the glomeruli. Clinically, patients present with a triad of symptoms: hematuria, proteinuria, and hypertension, often accompanied by acute kidney injury. Laboratory findings typically reveal significant proteinuria, often exceeding 3.5 grams per day, and the presence of red blood cell casts in the urine. Renal biopsy is crucial for diagnosis, showing diffuse mesangial hypercellularity and immune complex deposition. Management involves addressing the underlying cause, which may include immunosuppressive therapy, and supportive care for renal function. Early recognition and treatment are essential to prevent irreversible kidney damage.
Detailed clinical notes on symptoms, lab results, and treatment plans.
Patients presenting with acute kidney injury and nephritic syndrome.
Ensure all lab results, especially urinalysis and biopsy findings, are documented.
Comprehensive reports on renal biopsy findings.
Biopsy evaluations for suspected glomerulonephritis.
Pathology reports must clearly indicate the type of glomerular disease.
Used when a renal biopsy is performed to confirm diagnosis.
Document indication for biopsy and findings.
Nephrology specialists should ensure biopsy results are clearly linked to the diagnosis.
Key symptoms include hematuria, proteinuria, hypertension, and signs of acute kidney injury.
Diagnosis is typically made through clinical evaluation, urinalysis, and renal biopsy findings.
Treatment often involves immunosuppressive therapy and management of underlying conditions, along with supportive care for renal function.
